Latest advances and current challenges in the treatment of multiple myeloma

Nature Reviews Clinical Oncology

Volumn 9, Issue 3, 2012, Pages 135-143

  Mahindra, Anuj ^a   Laubach, Jacob ^b   Raje, Noopur ^a   Munshi, Nikhil ^b   Richardson, Paul G ^b   Anderson, Kenneth ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 8055; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; EVEROLIMUS; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; IMMUNOTOXIN; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; PANOBINOSTAT; PEPTIDE VACCINE; PERIFOSINE; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SOTATERCEPT; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG;

ACCESSORY CELL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; DOSE RESPONSE; DROWSINESS; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; GENE INACTIVATION; GENE OVEREXPRESSION; HEMATOLOGIC DISEASE; HIGH THROUGHPUT SCREENING; HUMAN; INFECTION; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN HOMEOSTASIS; PSMD4 GENE; RASD1 GENE; RASH; REVIEW; SENSORY NEUROPATHY; TARGET CELL; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT PLANNING; TREMOR; TUMOR GENE; TUMOR MICROENVIRONMENT; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PROGNOSIS; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS; PYRAZINES; THALIDOMIDE;

EID: 84857913363     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.15     Document Type: Review

References (123)

1. Kyle, R. A. & Rajkumar, S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23, 3-9 (2009).
2. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer. J. Clin. 60, 277-300 (2010).
3. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498 (2005). (Pubitemid 41007864)
4. San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906-917 (2008).
5. Palumbo, A. et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367, 825-831 (2006). (Pubitemid 43363369)
6. Barlogie, B. et al. Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J. Clin. Oncol. 28, 3023-3027 (2010).
7. Weber, D. M. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133-2142 (2007). (Pubitemid 350146108)
8. Dimopoulos, M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123-2132 (2007). (Pubitemid 350146107)
9. Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046-1060 (2011).
10. Anderson, K. C. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin. Cancer Res. 17, 1225-1233 (2011).
11. Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516-2520 (2008).
12. Kumar, S. K. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26, 149-157 (2011).
13. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498 (2005). (Pubitemid 41007864)
14. San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906-917 (2008).
15. Mahindra, A., Hideshima, T. & Anderson, K. C. Multiple myeloma: biology of the disease. Blood Rev. 24 (Suppl 1), S5-S11 (2010).
16. Palumbo, A. et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 22, 414-423 (2008). (Pubitemid 351255436)
17. Carrier, M., Le Gal, G., Tay, J., Wu, C. & Lee, A. Y. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J. Thromb. Haemost. 9, 653-663 (2011).
18. Lacy, M. Q. et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 118, 2970-2975 (2011).
19. Leleu, X. et al. High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009-02. ASH Annual Meeting Abstracts 118, 812 (2011).
20. Richardson, P. G. et al. Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): phase 2 results. ASH Annual Meeting Abstracts 118, 634 (2011).
21. Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412-3420 (2005).
22. Dewald, G. W. et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 106, 3553-3558 (2005). (Pubitemid 41609193)
23. Stewart, A. K. & Fonseca, R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J. Clin. Oncol. 23, 6339-6344 (2005). (Pubitemid 46218844)
24. Avet-Loiseau, H. et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 117, 2009-2011 (2011).
25. Dimopoulos, M. A. et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J. Clin. Oncol. 28, 4976-4984 (2010).
26. Varettoni, M. et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann. Oncol. 21, 325-330 (2010).
27. Short, K. D. et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25, 906-908 (2011).
28. Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (2003). (Pubitemid 36741588)
29. Rajkumar, S. V. et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24, 431-436 (2006). (Pubitemid 46630462)
30. Moreau, P. et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118, 5752-5758 (2011).
31. Orlowski, R. Z. et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 25, 3892-3901 (2007). (Pubitemid 47477266)
32. Richardson, P. G. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679-686 (2010).
33. Mitsiades, N. et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99, 4524-4530 (2002).
34. Richardson, P. G. et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J. Clin. Oncol. 27, 5713-5719 (2009).
35. Stewart, A. K. et al. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): The NCIC CTG MY.10 trial. ASH Annual Meeting Abstracts 116, 3 9 (2010).
36. Morgan, G. J. et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119, 7-15 (2011).
37. Attal, M. et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02. ASH Annual Meeting Abstracts 116, 310 (2010).
38. McCarthy, P. L. et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104. ASH Annual Meeting Abstracts 116, 37 (2010).
39. Rajkumar, S. V. Treatment of multiple myeloma. Nat. Rev. Clin. Oncol. 8, 479-491 (2011).
40. Stewart, A. K. et al. Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia 21, 2358-2359 (2007). (Pubitemid 350011711)
41. Cremer, F. W. et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 44, 194-203 (2005). (Pubitemid 41306648)
42. Chng, W. J., Ketterling, R. P. & Fonseca, R. Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. Genes Chromosomes Cancer 45, 1111-1120 (2006). (Pubitemid 44763439)
43. Shaughnessy, J. D. Jr. et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 118, 3512-3524 (2011).
44. Buda, G. et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann. Hematol. 89, 1133-1140 (2010).
45. Nojima, M. et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin. Cancer Res. 15, 4356-4364 (2009).
46. Bringhen, S. et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116, 4745-4753 (2010).
47. Moreau, P. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 12, 431-440 (2011).
48. Zangari, M. et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br. J. Haematol. 126, 715-721 (2004). (Pubitemid 39221309)
49. Palumbo, A. et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 22, 414-423 (2008). (Pubitemid 351255436)
50. Chen, C. et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br. J. Haematol. 146, 164-170 (2009).
51. Palumbo, A. et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 22, 414-423 (2008). (Pubitemid 351255436)
52. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01208662 (2011).
53. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT00522392?term=NCT00522392&rank1 (2010).
54. Chauhan, D. et al. Deubiquitylating enzyme USP-7, a novel therapeutic target in multiple myeloma. ASH Annual Meeting Abstracts 114, 610 (2009).
55. Chauhan, D. et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116, 4906-4915 (2010).
56. Parlati, F. et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114, 3439-3447 (2009).
57. Vij, R. et al. Final results from the Bortezomib-naive group of PX-171-004, a phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM. ASH Annual Meeting Abstracts 118, 813 (2011).
58. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01080391 (2011).
59. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01029054 (2011).
60. Chauhan, D. et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin. Cancer Res. 17, 5311-5321 (2011).
61. Chauhan, D. et al. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115, 834-845 (2010).
62. Richardson, P. G. et al. Phase 1 clinical evaluation of twice-weekly Marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 118, 302 (2011).
63. Singh, A. V. et al. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br. J. Haematol. 152, 155-163 (2011).
64. Kuhn, D. J. et al. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113, 4667-4676 (2009).
65. Hideshima, T. et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl Acad. Sci. USA 102, 8567-8572 (2005). (Pubitemid 40862776)
66. Santo, L. et al. Selective inhibition of HDAC6 with a new prototype inhibitor (ACY-1215) overcomes bortezomib resistance in multiple myeloma (MM). ASH Annual Meeting Abstracts 116, 2997 (2010).
67. McMillin, D. W. et al. MLN4924, a novel investigational NEDD8 activating enzyme inhibitor, exhibits preclinical activity in multiple myeloma and Waldenstrom's macroglobulinemia through mechanism distinct from existing proteasome inhibitors. ASH Annual Meeting Abstracts 116, 2988 (2010).
68. Hideshima, T. et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96, 2943-2950 (2000).
69. Mitsiades, N. et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99, 4525-4530 (2002). (Pubitemid 34627223)
70. Lacy, M. Q. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27, 5008-5014 (2009).
71. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01217957 (2011).
72. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01415882 (2011).
73. Santo, L. et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 29, 2325-2336 (2010).
74. Ghobrial, I. M. et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 12, 263-272 (2011).
75. Raje, N. et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104, 4188-4193 (2004). (Pubitemid 39620173)
76. Mahindra, A. et al. Updated results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma with pharmacodynamic and pharmacokinetic analysis. ASH Annual Meeting Abstracts 116, 3051 (2010).
77. Chauhan, D. et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 63, 6174-6177 (2003). (Pubitemid 37255160)
78. Hideshima, T. et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23, 8766-8776 (2004). (Pubitemid 39593291)
79. Hideshima, T. et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107, 4053-4062 (2006). (Pubitemid 43726814)
80. Richardson, P. G. et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J. Clin. Oncol. 29, 4243-4249 (2011).
81. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01002248 (2011).
82. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01118689 (2012).
83. Cirstea, D. et al. Disruption of DEPTOR/mTORC1/mTORC2 signaling cascade using a novel selective mTOR kinase inhibitor AZD8055 results in growth arrest and apoptosis in multiple myeloma cells. ASH Annual Meeting Abstracts 116, 791 (2010).
84. McMillin, D. W. et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 69, 5835-5842 (2009).
85. Mukherjee, S. et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J. Clin. Invest. 118, 491-504 (2008). (Pubitemid 351206540)
86. Breitkreutz, I. et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22, 1925-1932 (2008).
87. Morgan, G. J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989-1999 (2010).
88. Neri, P. et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin. Cancer Res. 13, 5903-5909 (2007). (Pubitemid 47583918)
89. Raje, N. S. et al. Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma [abstract]. ASCO Annual Meeting Abstracts, 2011. a29 (2011).
90. Fulciniti, M. et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114, 371-379 (2009).
91. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01337752 (2011).
92. Vallet, S. et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc. Natl Acad. Sci. USA 107, 5124-5129 (2010).
93. Bam, R. et al. Bruton's tyrosine kinase (BTK) is indispensable for myeloma cell migration towards SDF-1 and induction of osteoclastogenesis and osteolytic bone disease. ASH Annual Meeting Abstracts 116, 447 (2010).
94. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01478581 (2011).
95. Tai, Y. T. et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112, 1329-1337 (2008).
96. Richardson, P. G. et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: interim results of a phase 2 study. ASH Annual Meeting Abstracts 116, 986 (2010).
97. de Weers, M. et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186, 1840-1848 (2011).
98. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01421186 (2011).
99. Ikeda, H. et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15, 4028-4037 (2009).
100. Chanan-Khan, A. A. et al. Phase I study of BT062 given as repeated single dose once every 3 weeks in patients with relapsed or relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 114, 1862 (2009).
101. Alici, E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr. Opin. Mol. Ther. 12, 724-733 (2010).
102. Shi, J. et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br. J. Haematol. 143, 641-653 (2008).
103. Rosenblatt, J. et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117, 393-402 (2011).
104. Szmania, S. et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J. Immunother. 30, 847-854 (2007). (Pubitemid 350295364)
105. Blotta, S. et al. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood 114, 3276-3284 (2009).
106. Bae, J. et al. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia 25, 1610-1619 (2011).
107. Peacock, C. D. et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl Acad. Sci. USA 104, 4048-4053 (2007). (Pubitemid 47181576)
108. Nefedova, Y., Sullivan, D. M., Bolick, S. C., Dalton, W. S. & Gabrilovich, D. I. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 111, 2220-2229 (2008). (Pubitemid 351451536)
109. Sukhdeo, K. et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc. Natl Acad. Sci. USA 104, 7516-7521 (2007). (Pubitemid 47185938)
110. Von Hoff, D. D. et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164-1172 (2009).
111. Rudin, C. M. et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361, 1173-1178 (2009).
112. Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
113. Hadari, Y. & Schlessinger, J. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J. Clin. Invest. 119, 1077-1079 (2009).
114. Qing, J. et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest. 119, 1216-1229 (2009).
115. Martinez-Garcia, E. et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117, 211-220 (2011).
116. Marango, J. et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 111, 3145-3154 (2008).
117. McMillin, D. W. et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 16, 483-489 (2010).
118. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01416428 (2011).
119. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01311687 (2011).
120. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01239797 (2012).
121. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01335339 (2012).
122. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01323751 (2011).
123. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/ct2/show/NCT01023308 (2011).